Dr Reddy's To Launch Generic Obesity Drugs In 87 Countries To Compete Wegovy

Dr Reddy's Laboratories plans to introduce a more affordable version of Novo Nordisk's weight-loss drug, Wegovy, in 87 countries next year. This announcement was made by the company's CEO, Erez Israeli. The Indian pharmaceutical company aims to tap into the growing global obesity drug market, which is projected to reach $150 billion in sales by the early 2030s.

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging markets. The launch is contingent upon patent expirations. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli stated during a press conference discussing the company's earnings.

Global Obesity Drug Market

The demand for obesity drugs has surged following successful launches by Novo Nordisk and Eli Lilly. Other Indian pharmaceutical companies like Cipla, Lupin, Biocon, and Sun Pharma are also planning to release generic versions of these weight-loss medications. These drugs belong to a class known as GLP-1 receptor agonists that help regulate blood sugar and slow digestion.

Novo Nordisk recently introduced Wegovy in India after Eli Lilly launched Mounjaro for weight-loss and diabetes management. Dr Reddy's anticipates that their generic drug could generate 'hundreds of millions of dollars' in sales for the company.

Patent Expirations and Legal Challenges

The patent for semaglutide is expected to expire in several countries next year, including India in March. In May, Novo Nordisk filed a lawsuit against Dr Reddy's alleging patent infringement related to semaglutide. Despite this legal challenge, Dr Reddy's has submitted regulatory applications in all targeted countries for their generic version.

Dr Reddy's Laboratories is not alone in its ambitions; it plans to launch 26 GLP-1 drugs over the next decade. This move aligns with the company's strategy to capture a significant share of the burgeoning obesity drug market.

The race among pharmaceutical companies to secure a portion of this lucrative market continues as they prepare for upcoming patent expirations and navigate legal hurdles. The competition underscores the high stakes involved as companies vie for dominance in this rapidly expanding sector.